View clinical trials related to Classical Hodgkin's Lymphoma.
Filter by:Patients with refractory cHL. Patients will be treated with GLS-010
This study evaluated the efficacy of oral panobinostat in participants with refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with high dose chemotherapy and autologous stem cell transplant. Safety of panobinostat also was assessed. Other markers that may correlate with efficacy or safety were explored.